VEGF Trap-Eye For Wet Age-related Macular Degeneration Unanimously Approved By FDA Panel

VEGF Trap-Eye, used for the treatment of the neovascular form of age-related macular degeneration (wet AMD), a condition that can lead to blindness, has been approved by a 10 to 0 FDA Panel vote. The treatment is approved for administration every other month at a dose of 2 milligrams, the panel recommended, which gives it an edge over rival Lucentis which needs to be used monthly. VEFG Trap-Eye has the proposed brand name Eylea. VEGF Trap-Eye is made by Regeneron Pharmaceuticals, Inc. Regeneron's shares were halted on Nasdaq, pending the results of the vote...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/FhgXwquzzPc/228931.php

weight loss lifestyle